MENU
+Compare
RANI
Stock ticker: NASDAQ
AS OF
Jul 3, 12:24 PM (EDT)
Price
$0.54
Change
+$0.01 (+1.89%)
Capitalization
17.85M

RANI Rani Therapeutics Holdings Forecast, Technical & Fundamental Analysis

Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections... Show more

RANI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for RANI with price predictions
Jul 02, 2025

RANI's Stochastic Oscillator entering oversold zone

The Stochastic Oscillator for RANI moved into oversold territory on July 02, 2025. Be on the watch for the price uptrend or consolidation in the future. At that time, consider buying the stock or exploring call options.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where RANI's RSI Indicator exited the oversold zone, of 28 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on July 02, 2025. You may want to consider a long position or call options on RANI as a result. In of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where RANI advanced for three days, in of 213 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where RANI declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for RANI entered a downward trend on July 02, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.381) is normal, around the industry mean (16.522). P/E Ratio (0.000) is within average values for comparable stocks, (58.479). RANI's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.315). Dividend Yield (0.000) settles around the average of (0.041) among similar stocks. P/S Ratio (13.441) is also within normal values, averaging (261.553).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. RANI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RANI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
RANI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

RANI is expected to report earnings to rise 31.82% to -28 cents per share on August 07

Rani Therapeutics Holdings RANI Stock Earnings Reports
Q2'25
Est.
$-0.29
Q1'25
Beat
by $0.02
Q4'24
Missed
by $0.01
Q3'24
Beat
by $0.05
Q2'24
Beat
by $0.08
The last earnings report on May 13 showed earnings per share of -21 cents, beating the estimate of -23 cents. With 30.04K shares outstanding, the current market capitalization sits at 17.85M.
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
2051 Ringwood Avenue
Phone
+1 408 457-3700
Employees
140
Web
https://www.ranitherapeutics.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
NBR31.361.78
+6.02%
Nabors Industries Ltd
RNA29.370.91
+3.20%
Avidity Biosciences
ESOA10.240.30
+3.02%
Energy Services of America Corp
BRFH3.35N/A
N/A
Barfresh Food Group
NWG13.01-0.88
-6.34%
NatWest Group plc

RANI and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, RANI has been loosely correlated with XENE. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if RANI jumps, then XENE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RANI
1D Price
Change %
RANI100%
+3.56%
XENE - RANI
36%
Loosely correlated
+6.61%
ADVM - RANI
32%
Poorly correlated
-0.88%
DRUG - RANI
31%
Poorly correlated
+5.38%
UBX - RANI
31%
Poorly correlated
-13.14%
VNDA - RANI
30%
Poorly correlated
+4.49%
More